Cargando…
Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287893/ https://www.ncbi.nlm.nih.gov/pubmed/25010055 http://dx.doi.org/10.1038/gim.2014.79 |
| _version_ | 1782351876873781248 |
|---|---|
| author | Pisani, Antonio Riccio, Eleonora Sabbatini, Massimo |
| author_facet | Pisani, Antonio Riccio, Eleonora Sabbatini, Massimo |
| author_sort | Pisani, Antonio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4287893 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42878932015-01-13 Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? Pisani, Antonio Riccio, Eleonora Sabbatini, Massimo Genet Med Commentary Nature Publishing Group 2015-01 2014-07-10 /pmc/articles/PMC4287893/ /pubmed/25010055 http://dx.doi.org/10.1038/gim.2014.79 Text en Copyright © 2014 American College of Medical Genetics and Genomics http://creativecommons.org/licenses/by/3.0/ This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/ |
| spellingShingle | Commentary Pisani, Antonio Riccio, Eleonora Sabbatini, Massimo Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? |
| title | Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? |
| title_full | Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? |
| title_fullStr | Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? |
| title_full_unstemmed | Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? |
| title_short | Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? |
| title_sort | agalsidase alfa and agalsidase beta in the treatment of fabry disease: does the dose really matter? |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287893/ https://www.ncbi.nlm.nih.gov/pubmed/25010055 http://dx.doi.org/10.1038/gim.2014.79 |
| work_keys_str_mv | AT pisaniantonio agalsidasealfaandagalsidasebetainthetreatmentoffabrydiseasedoesthedosereallymatter AT riccioeleonora agalsidasealfaandagalsidasebetainthetreatmentoffabrydiseasedoesthedosereallymatter AT sabbatinimassimo agalsidasealfaandagalsidasebetainthetreatmentoffabrydiseasedoesthedosereallymatter |